Viral hepatitis;Virushepatitis

Therapeutische Umschau

Volumn 68, Issue 4, 2011, Pages 175-181

  Moradpour, Darius ^a   Blum, Hubert E ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEPATITIS; ARTICLE; CHRONIC HEPATITIS; DISEASE ASSOCIATION; DISEASE COURSE; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HEPATITIS E VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORBIDITY; MORTALITY; VIROLOGY; VIRUS DIAGNOSIS; VIRUS HEPATITIS; VIRUS TRANSMISSION;

CARCINOMA, HEPATOCELLULAR; HEPATITIS, CHRONIC; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; RISK FACTORS;

EID: 79953297348     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930/a000147     Document Type: Article

References (20)

1. Martin A, Lemon SM. Hepatitis A virus: from discovery to vaccines. Hepatology 2006; 43: S164-72.
2. Wheeler C, Vogt TM, Armstrong GL, et al. An outbreak of hepatitis A associated with green onions. N Engl J Med 2005; 353: 890-7.
3. Victor JC, Monto AS, Surdina TY, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007; 357: 1685-94.
4. Bruix J, Sherman M. AASLD Practice Guideline: Management of he-patocellular carcinoma-an update. Hepatology 2011, in press.
5. EASL Clinical Practice Guideline: Management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
6. Lok ASF, McMahon BJ. AASLD Practice Guideline: Chronic Hepatitis B: update 2009. Hepatology 2009; 50: 1-36.
7. Zoulim, F, Locarnini, S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-608.
8. Pinzani M, Vizzutti F, Arena U, et al. Noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gas-troenterol Hepatol 2008; 5: 95-106.
9. Ghany MG, Strader DB, Thomas DL, et al. AASLD Practice Guideline: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
10. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
11. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-63.
12. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-50.
13. McHutchison JG, Everson GT, Gor-don SC, et al. Telaprevir with pegin-terferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
14. McHutchison JG, Manns M P, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
15. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and rib-avirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-16.
16. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastro-enterol Hepatol 2010; 7: 31-40.
17. Meng XJ. Recent advances in hepatitis E virus. J Viral Hepat 2010; 17: 153-61.
18. Purcell RH, Emerson SU. Hidden danger: the raw facts about hepatitis E virus. J Infect Dis 2010; 202: 819-21.
19. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ transplant recipients. N Engl J Med 2008; 358: 811-7.
20. Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombi-nant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376: 895-902.